These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 334187)

  • 41. The antimicrobial activities of trimethoprim and sulfonamides.
    Burman LG
    Scand J Infect Dis; 1986; 18(1):3-13. PubMed ID: 3515508
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Trimethoprim and sulfonamide. A chemotherapeutically effective combination with 2 points of attack].
    Gladtke E
    MMW Munch Med Wochenschr; 1978 Aug; 120(32-33):1059-62. PubMed ID: 307679
    [No Abstract]   [Full Text] [Related]  

  • 43. Bacteriostatic and bactericidal activity of two trimethoprim-sulfonamide combinations.
    Böhni E
    Chemotherapy; 1976; 22(3-4):262-73. PubMed ID: 1269292
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The joint effects of sulfonamides and their potentiator on Photobacterium phosphoreum: differences between the acute and chronic mixture toxicity mechanisms.
    Zou X; Lin Z; Deng Z; Yin D; Zhang Y
    Chemosphere; 2012 Jan; 86(1):30-5. PubMed ID: 21944043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nature of the bacterial action of sulfonamides and trimethoprim, alone and in combination.
    Then R; Angehrn P
    J Infect Dis; 1973 Nov; 128():Suppl:498-501. PubMed ID: 4585954
    [No Abstract]   [Full Text] [Related]  

  • 46. Mechanisms of resistance to trimethoprim, the sulfonamides, and trimethoprim-sulfamethoxazole.
    Then RL
    Rev Infect Dis; 1982; 4(2):261-9. PubMed ID: 7051228
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part I: Comparison of the antibacterial effect of sulphonamides alone and in combination with trimethoprim.
    Ekström B; Forsgren U; Ortengren B; Bergan T
    Infection; 1979; 7 Suppl 4():S359-66. PubMed ID: 389812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis.
    Reed MD; Stern RC; Bertino JS; Myers CM; Yamashita TS; Blumer JL
    J Pediatr; 1984 Feb; 104(2):303-7. PubMed ID: 6607329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of sulfamethoxazole and trimethoprim association in hens.
    Queralt J; Castells I
    Poult Sci; 1985 Dec; 64(12):2362-7. PubMed ID: 4095069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of cell wall synthesis by sulfonamides and trimethoprim.
    Daschner F
    Chemotherapy; 1976; 22(1):12-8. PubMed ID: 767064
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei.
    Wallace RJ; Jones DB; Wiss K
    Rev Infect Dis; 1981; 3(5):898-904. PubMed ID: 7339821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A correlation with type of sulfonamide resistance gene in Escherichia coli and synergy between trimethoprim and sulfamethoxazole.
    Valentine CR; Hawk JM; Christian MM; Youmans RW
    J Basic Microbiol; 1992; 32(3):201-7. PubMed ID: 1512711
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The bacteriostatic mechanisms of sulfonamido-trimethoprim combinations.
    Toth-Martinez BL
    Biochem Pharmacol; 1977 Mar; 26(6):451-6. PubMed ID: 322667
    [No Abstract]   [Full Text] [Related]  

  • 54. Effects of trimethoprim on leukaemic cells in vitro.
    Rivard GE; Momparler LF; Momparler RL
    Br J Haematol; 1981 Feb; 47(2):221-6. PubMed ID: 6970589
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Trimethoprim: clinical use and pharmacokinetics.
    Friesen WT; Hekster YA; Vree TB
    Drug Intell Clin Pharm; 1981 May; 15(5):325-30. PubMed ID: 7023899
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of trimethoprim and sulfamethoxazole on the synthesis, expression, and function of type 1 fimbriae of Escherichia coli.
    Schifferli DM; Abraham SN; Beachey EH
    J Infect Dis; 1986 Sep; 154(3):490-6. PubMed ID: 2874179
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increasing resistance to trimethoprim-sulfamethoxazole among isolates of Escherichia coli in developing countries.
    Murray BE; Alvarado T; Kim KH; Vorachit M; Jayanetra P; Levine MM; Prenzel I; Fling M; Elwell L; McCracken GH
    J Infect Dis; 1985 Dec; 152(6):1107-13. PubMed ID: 3905979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antimicrobial susceptibility, growth kinetic and pathogenicity of thymidine-requiring Streptococcus species.
    Fu KP; Kimble EF; Coldreck RJ; Konopka EA
    Chemotherapy; 1984; 30(6):373-8. PubMed ID: 6335073
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Editorial: Trimethoprim-sulfamethoxazole (TMP-SMZ)--better late than never.
    Vaisrub S
    JAMA; 1974 Mar; 227(12):1423. PubMed ID: 4205718
    [No Abstract]   [Full Text] [Related]  

  • 60. The biochemical basis of the antimicrobial action of sulfonamides and trimethoprim in vivo--I. Action of sulfonamides and trimethoprim in blood and urine.
    Then R; Angehrn P
    Biochem Pharmacol; 1974 Nov; 23(21):2977-82. PubMed ID: 4611429
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.